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ABSTRACT 
Tuberculosis (TB) is primarily a lung disease (pulmonary tuberculosis, PTB) but the bacilli can also develop in other places in 
the body, such as the bones, liver and kidney as extra pulmonary tuberculosis. Hepatic and renal involvements in PTB patients 
are mostly secondary to TB chemotherapy that is potentially hepato- and nephro- toxic. In this study, the biochemical 
parameters that indicate renal and hepatic involvements were analyzed in the sera of MDR-TB patients with and without HIV 
co-infection prior to commencement of chemotherapy. Out of 115 MDR-TB patients (76 males and 39 females) recruited for the 
study, 22 patients (11 males and 11 females) were co-infected with HIV. Serum levels of sodium (Na+), potassium (K+), chloride 
(Cl-) were analyzed using Easylite (ISE technology), bicarbonate (HCO3-) was analysed using back titration method, urea and 
creatinine were determined spectrophotometrically using Diacetlymonoxime (DAM) method and Jaffe’s alkaline picrate 
method respectively. Total and direct bilirubin, serum glutamate oxaloacetate transferase (SGOT), serum glutamate pyruvate 
transferase (SGPT), alkaine phosphatase(ALP), total protein (TP) and albumin (Alb) were determined using Hitachi 912 
autoanalyzer. There were no statistical significant differences in the renal and hepatic parameters of TB patients with HIV 
compared with TB patients without HIV. However, significantly higher proportions (89%) of MDR-TB patients had their SGOT 
within reference range. The mean values indicate that HIV infection did not significantly alter renal and hepatic profiles in 
MDR-TB patients prior to treatment. 
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RESUME : 
La tuberculose est principalement une maladie du poumon (Tuberculeuse pulmonaire TBP) mais les bacilles peuvent être 
également se développer dans d’autres endroits dans le corps, tels que les os, le foie et les reins comme la tuberculose extra 
pulmonaire. L’atteinte hépatique et rénale chez les patients atteints de TBP est surtout secondaire a la chimiothérapie de la 
tuberculose(TB) qui est potentiellement hépato – et néphro – toxique. Dans cette étude, les paramètres biochimiques qui 
indiquent les implications rénales et hépatiques ont été analyses dans les sérums des patients atteints de MDR – TB avec ou 
sans Co – infection par le VIH avant le commencement de la chimiothérapie. Sur les 115 patients atteints de MDR – TB (76 
males et femelles), recrutés pour l’étude, 22 patients (11 males et femelles) ont été co – infectes par le VIH. Le niveau sérique de 
sodium (Na⁺), de potassium (K⁺), le chlorure(C1⁻) ont été analyses en utilisant Easylite(technologie ISE), le bicarbonate (HC0₃⁻) a 
été analyse en utilisant la méthode de titrage de retour, l’urée et de la créatinine ont été déterminés spectrophotométrie rn 
utilisant la méthode Diacétyle monoxime(DAM) et la méthode de picrate alcaline de Jaffer respectivement. Bilirubine totale et 
directe, glutamate oxaloacetate transférase sérique(SGOT), transférase sérique de glutamate pyruvate(SGPT), phosphatase 
alcaline(ALP), protéines totale(TP) et albumine(Alb) ont été déterminés en utilisant Hitachi 912 autoanalyseur. Il n’ ya pas de 
différence statistiquement significative dans les paramètres rénales et hépatiques des patients tuberculeux vivant avec ke VIH 
par rapport aux patients atteints de tuberculose sans VIH. Néanmoins, les proportions significativement élevées (89%) des 
patients atteints de MDR – TB ont eu leurs SGOT a porté de référence. Les valeurs moyennes indiquent que l’infection par le 
VIH n’a pas modifié significativement les profils rénaux et hépatiques chez les patients de TB – MRD. 
Mots – clés : Les reins, le foie, l’électrolyte, la tuberculose, Virus de l’immunodéficience humaine, Co – infection. 
  





TB is an air-borne infectious disease caused by 
bacteria Mycobacterium tuberculosis, which primarily 
affects the lungs. The World Health Organization 
(WHO) declared Tuberculosis (TB) a global 
emergency in 1993 and it remains one of the world’s 
major causes of illness and death. One third of the 
world’s population carries the TB bacteria and more 
than nine million of these become sick each year with 
active TB (1). TB disproportionately affects people in 
resource-poor settings, particularly in Africa and Asia 
during their most productive years (2). Coupled with 
the pandemic of HIV, TB has become an important 
cause of morbidity and mortality world-wide (3). TB 
is a major public health problem in Nigeria, with the 
country ranking 5th among the 22 high TB burden 
countries which collectively bear 80% of the global 
burden of TB. The TB burden in Nigeria is further 
compounded by HIV/AIDS epidemic and the 
emergence of multi-drug resistant tuberculosis (MDR-
TB) (2). 
It was reported that systemic effects especially on 
vital organs such as the kidneys and liver are later 
events that characterize tuberculosis (TB) and Human 
Immunodeficiency (HIV) infections. There can be 
direct renal and hepatic involvement in TB patients 
but this rarely causes marked impaired renal and 
hepatic functions. Occasionally, local signs and 
symptoms may be prominent in renal and hepatic 
tuberculosis, and may constitute the initial or sole 
presenting feature of the disease (4). Anti- tubercular 
drugs was reported to cause renal and hepatic 
injuries. Rifampicin, pyrazinamide, isoniazid and 
ethambutol were shown to benephro- and hepato- 
toxic drugs (5). A study showed that patients with 
chronic kidney and liver disease can also develop 
tuberculosis (6), thus posing special management 
problems for the TB. Since many of the potent anti-
tubercular drugs are nephrotoxic and hepatotoxic, 
they may aggravate the underlying disease processes. 
Thus, anti-TB drug regimens need to be monitored to 
prevent further renal and hepatic insult in the 
patients. 
Moreover, literatures have shown that a single anti-
TB drug has side effects on liver and kidney (5, 6), 
thus it is likely that combination of drugs in MDR-TB 
patients or co-existence of MDR-TB with HIV may 
have severe effects on kidneys and liver of these 
patients. This therefore demands for the need to 
evaluate the status ofliver and kidney functions in 
MDR-TB patients before commencement of multi-
drug treatment.  
MATERIALS AND METHODS                                      
After obtaining informed consent, a total of 115 TB 
patients consisting of 76 males (37±11 years) and 39 
females (30±8 years) admitted into MDR-TB 
Treatment Center, University College Hospital, 
Ibadan, Nigeria, were recruited into the study. 
Twenty-two(22) patients (33±9 years) made up of 11 
males ((32±9 years) and 11 females(26±8years)were 
co-infected with HIV. Five (5) ml of blood samples 
were collected to plain bottles. Serum was obtained 
following centrifugation. Serum bilirubin was 
estimated by photometric method based on the diazo 
reaction. This was based on the principle that 
bilirubin reacts with diazotized sulphanilic acid to 
form the red colour azobilirubin (7).Serum protein 
was analyzed using Biuret method in which divalent 
copper reacts in alkaline solution with protein peptide 
bonds to form the characteristic purple-coloured 
Biuret complex. The colour intensity is directly 
proportional to the protein concentration which was 
determined photometrically (8). Albumin was 
determined by dye binding method whereat a pH 
value of 4.1 albumin displays a sufficiently cationic 
character to be able to bind with bromocresol green 
(BCG), an anionic dyestuff to form a blue –green 
complex (9). Urea was estimated using Diacetyl 
monoxime method where heating urea with 
substances such as diacetyl formed coloured 
compound measurable spectrophotometrically at 
520nm (10). Creatinine was determined using Jaffe’s 
alkaline picrate method where creatinine reacts with 
picric acid in an alkaline solution toproduce a deep 
yellow complex directly proportional to the level of 
creatinine present in the sample (10). ALP activity 
was assayed using kinetic methodby measuring the 
concentration of p-nitrophenol released from the 
cleavage of p-nitrophenyl phosphate into phosphate 
and p-nitrophenol(11). ASTand ALT activitywere 
determined following the principle described by 
Reitman and Frankel(1953). AST was measured by 
monitoring the concentration of oxaloacetate 
hydrazone formed with 2, 4-dinitrophenylhydrazine 
while ALT was measured by monitoring the 
concentration of pyruvate hydrazone formed with 2, 
4-dinitrophenylhydrazine (12). GGTactivity was 
assayed by monitoringthe concentration of 5-amino-2-
nitrobenzoate released (13). Serum levels of sodium 
(Na+), potassium (K+), chloride (Cl-) were analyzed 
using Easylite (ISE technology), bicarbonate (HC03-) 
was determined using back titration method (14). The 
data were presented in mean ± S.D. The differences 
between the means were compared using Mann-
whitney U test. 
RESULTS                                                                        
Table 1 shows demographic characteristics of MDR-
TB patients with and without HIV infection and their 
gender distribution. Age, height, weight and BMI 
were similar in MDR-TB patients compared with 
patients having MDR-TB/HIV co-infection. 




Table 2 shows that there were no significant 
differences in renal and hepatic profiles of the MDR-
TB patients compared with patients having MDR-
TB/HIV co-infection.  
Table 3 shows percentage of parameters below, 
within and above reference range (RR). SGOT was 
significantly above normal reference range in 
most(74.2%) of MDR-TB patients.  
 
TABLE 1: DEMOGRAPHIC CHARACTERISTICS OF MDR-TB PATIENTS AND MDR-TB/HIV PATIENTS 
 MDR-TB (n= 93) MDR-TB/HIV (n= 22) p-values 

























TABLE 2: RENAL AND HEPATIC PROFILES IN MDR-TB PATIENTS AND MDR-TB/HIV PATIENTS 



































































TABLE 3: RENAL AND HEPATIC PARAMETERS IN MDR-TB AND MDR-TB/HIV PATIENTS WITHIN AND OUTSIDE 
REFERENCE RANGES (RR) 




Creatinine:     
Within RR 
Above RR 











Direct Bilirubin:  
Within RR 
Above RR 





















































0  (0.0%) 
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Renal and hepatic profiles of male MDR-TB compared 
with female MDR-TB patients were shown in Table 4. 
Serum creatinine was significantly raised in male 
MDR-TB patients compared with female MDR-TB 
patients. Tables 5 and 6 respectively show hepatic and 
renal profiles in male or female MDR-TB patients 
compared with MDR-TB/HIV co-infection. There 
were no statistical significant differences between the 
parameters in male patients compared with female 
patients. 
TABLE 4: RENAL AND HEPATIC PROFILES IN MALE AND FEMALE MDR-TB PATIENTS 







Total Bilirubin (mg/dl) 














































TABLE 5: HEPATIC AND RENAL PROFILES IN MALE MDR-TB PATIENTS AND MDR-TB/HIV PATIENTS 


























































TABLE 6: HEPATIC AND RENAL PROFILES IN FEMALE MDR-TB PATIENTS AND MDR-TB/HIV PATIENTS 























































Chemotherapy is the basic approach to clinical 
tuberculosis control. Previous study have reported 
that antituberculosis therapy (ATT) causes 
derangement of hepatic and renal functions (15) but 
influence of HIV co-infection and combination of ATT 
on renal and hepatic profile was not reported. The 
primary purpose of this study was to determine the 
base line serum levels of renal and hepatic parameters 
in MDR-TB patients without HIV infection compared 
with MDR-TB/HIV co-infection before 
commencement of multi-drug therapy for MDR-TB 
patients. This allows early detection of possible 
hepatic or renal defect and thus necessitating more 
appropriate management strategies.  
To the best of our knowledge, this is the first study 
that will monitor renal and kidney functions in 
patients with co-infection of MDR-TB and HIV at 
initiation of therapy in this environment. Renal- and 
hepatic- parameters measured in MDR-TB patients 
with HIV infection were not statistically different 
compared with MDR-TB patients without HIV 
infection. However, higher proportions of MDR-TB 
patients have their SGOT above normal reference 
range.Previous authors have reported raised 
transaminases as early sign of liver involvement in 
TB/HIV pathology (16). Also, renal- and hepatic- 
parameters in male or female MDR-TB patients with 
HIV infection did not show any statistical significance 
differences when compared with MDR-TB patients 
without HIV co-infection. However, serum creatinine 
in male MDR-TB patients was significantly raised 
compared with female MDR- TB patients. This might 
be related to higher muscle mass in males compared 
with females. Although, this has no clinical 
implication but this study recommends that creatinine 
should be frequently monitored in these patients 
since raised creatinine is a sensitive and specific 
marker of kidney damage.  Besides this, regular 
biochemical investigations should also be performed 
essentially to predict when the patients are likely to 
develop hepatic and renal function derangements. 
According to Ciba Laboratories, kidney and liver 
function tests should be carried out before initiating 
ATT (17) as it has been reported that patients with 
abnormal baseline transaminases levels are at 
increased risk of developing hepatic injury eventually 
(16). It was reported that renal and hepatic profiles 
should be determined twice weekly for the first two 
weeks followed by weekly monitoring till the end of 
two months and then monthly investigations till the 
end of the treatment (18). This is not affordable in 
patients in resource poor countries, thus a single 




The results indicate that HIV infection did not 
significantly alter renal and hepatic profiles in MDR-
TB patients prior to treatment. However, since the 
current recommended treatment anti-tuberculosis 




drugs are found to be potentially nephrotoxic and 
hepatotoxic, continuous monitoring of hepatic and 
renal functions of MDR-TB patients is necessary.  
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